PharmaCyte Biotech Inc PMCB Q1 2026 Earnings PreRevenue Biotech Reports Wider Loss Amid Strategic Pipeline Progress Xi and Putin Reaffirm Multipolar Vision in Beijing Summit Following Trumps Diplomatic Visit Kustom Entertainment KUST Q4 2025 Underperforms Key Challenges Ahead VS Q4 2025 Earnings Net Loss Per Share of 020 Amid Zero Revenue Stock Rises 283